Search research articles
Contact Us
Filters
Showing results (21-30 of 77) with videos related to
Page
of 8
Sort By:
Neuropsychiatric Disease and Treatment
|
March 13, 2019
Durability of symptomatic responses obtained with adjunctive vagus nerve stimulation in treatment-resistant depression
Arun Kumar, Mark T Bunker, Scott T Aaronson, et al.
Journal of Affective Disorders
|
September 30, 2021
Systematic review of preservation TMS that includes continuation, maintenance, relapse-prevention, and rescue TMS
Saydra Wilson, Paul E Croarkin, Scott T Aaronson, et al.
The Journal of Clinical Psychiatry
|
May 15, 2026
Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation: An Open-Label Trial
Andrew van der Vaart, Jeffrey LaPratt, Kimberly Swartz, et al.
Schizophrenia Research
|
June 1, 2014
Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia
Maju Mathew Koola, Robert W Buchanan, Anilkumar Pillai, et al.
Schizophrenia Research
|
July 15, 2017
Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments
Maju Mathew Koola, Jennifer Sklar, Whitney Davis, et al.
Brain Stimulation
|
October 12, 2023
Dosing transcranial magnetic stimulation in major depressive disorder: Relations between number of treatment sessions and effectiveness in a large patient registry
Todd M Hutton, Scott T Aaronson, Linda L Carpenter, et al.
Journal of Affective Disorders
|
August 18, 2020
Clinical outcomes in a large registry of patients with major depressive disorder treated with Transcranial Magnetic Stimulation
Harold A Sackeim, Scott T Aaronson, Linda L Carpenter, et al.
The American Journal of Psychiatry
|
January 1, 2025
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial
Scott T Aaronson, Andrew van der Vaart, Tammy Miller, et al.
JAMA Psychiatry
|
December 6, 2023
Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial
Scott T Aaronson, Andrew van der Vaart, Tammy Miller, et al.
International Journal of Bipolar Disorders
|
May 3, 2020
The effects of vagus nerve stimulation on the course and outcomes of patients with bipolar disorder in a treatment-resistant depressive episode: a 5-year prospective registry
R Hamish McAllister-Williams, Soraia Sousa, Arun Kumar, et al.
Page
of 8
Search research articles
Search
Showing results (21-30 of 77) with videos related to
Sort By:
Page
of 8
Neuropsychiatric Disease and Treatment
|
March 13, 2019
Durability of symptomatic responses obtained with adjunctive vagus nerve stimulation in treatment-resistant depression
Arun Kumar, Mark T Bunker, Scott T Aaronson, et al.
Journal of Affective Disorders
|
September 30, 2021
Systematic review of preservation TMS that includes continuation, maintenance, relapse-prevention, and rescue TMS
Saydra Wilson, Paul E Croarkin, Scott T Aaronson, et al.
The Journal of Clinical Psychiatry
|
May 15, 2026
Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation: An Open-Label Trial
Andrew van der Vaart, Jeffrey LaPratt, Kimberly Swartz, et al.
Schizophrenia Research
|
June 1, 2014
Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia
Maju Mathew Koola, Robert W Buchanan, Anilkumar Pillai, et al.
Schizophrenia Research
|
July 15, 2017
Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments
Maju Mathew Koola, Jennifer Sklar, Whitney Davis, et al.
Brain Stimulation
|
October 12, 2023
Dosing transcranial magnetic stimulation in major depressive disorder: Relations between number of treatment sessions and effectiveness in a large patient registry
Todd M Hutton, Scott T Aaronson, Linda L Carpenter, et al.
Journal of Affective Disorders
|
August 18, 2020
Clinical outcomes in a large registry of patients with major depressive disorder treated with Transcranial Magnetic Stimulation
Harold A Sackeim, Scott T Aaronson, Linda L Carpenter, et al.
The American Journal of Psychiatry
|
January 1, 2025
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial
Scott T Aaronson, Andrew van der Vaart, Tammy Miller, et al.
JAMA Psychiatry
|
December 6, 2023
Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial
Scott T Aaronson, Andrew van der Vaart, Tammy Miller, et al.
International Journal of Bipolar Disorders
|
May 3, 2020
The effects of vagus nerve stimulation on the course and outcomes of patients with bipolar disorder in a treatment-resistant depressive episode: a 5-year prospective registry
R Hamish McAllister-Williams, Soraia Sousa, Arun Kumar, et al.
Page
of 8